Skip to content

Released Sep 24, 2024, after the close

10-Q filed Sep 24, 2024, 86 days after period end · 0001683168-24-006623

Q2 2024 · 10-Q
Revenue—
Net Income-$6.57MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$4.20N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$5,435,449N/M
Operating Cash Flowderived-$2,673,638—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2024Q2 2023
Net Income-$6.57M-$5.52M
EPS Diluted-$4.20-$3.88

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR